Brought to you by 
Roivant Sciences raises $200mm in private placement
14 Nov 2018
Executive Summary
Roivant Sciences GMBH raised $200mm in a private placement financing ($7bn post-money valuation) with new investors NovaQuest Capital Management, RTW Investments and other large institutional asset managers. All previous institutional shareholders also participated in the financing. The company will use the offering proceeds to launch additional "Vants" (entrepreneurial biotech and healthcare tech companies) for innovative medicines and technologies. Since Roivant's last financing in 2017, the company has grown its therapies in development from 14 to 34 and its Vants from 6 to 14.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com